Vol 11 (June 30, 2026): Annals of Blood

Editorial Commentary 
Bexmarilimab and azacitidine: promise for immunotherapy in myelodysplastic syndrome?
Gina Keiffer, Margaret Kasner
Annals of Blood  
2026;
11:
20
.
Editorial Commentary 
Venetoclax and azacitidine in high-risk myelodysplastic syndromes: expectations vs. evidence
Angelo Rizzolo, Andrea Palasciano, Sarit Assouline
Annals of Blood  
2026;
11:
19
.
Editorial Commentary 
Chronic graft-versus-host disease: toward mechanism-based prevention and treatment
Angélica Villanueva Freije, Antonio Pérez-Martínez
Annals of Blood  
2026;
11:
18
.
Case Report 
APTT dynamics after susoctocog alfa for early diagnostic support in suspected acquired hemophilia A: a case report
Eiichiro Nagatani, Takeshi Hagino, Tomohiko Sato, Manabu Kamio
Annals of Blood  
2026;
11:
17
.
Case Report 
Transfusion-acquired transient hemoglobinopathies: a case report and review of the literature
Katherine Drews-Elger, Thomas J. Harrington, Afshan Idrees, Yanyun Wu, Derek C. Waggoner
Annals of Blood  
2026;
11:
16
.
Review Article 
Blood transfusion thresholds: a narrative review of the literature and recent guidelines
Opal Reddy, Gaurav K. Gupta, Sushant Kumar Meinia, Zaher K. Otrock, J. Peter R. Pelletier, Maria Roussakis, Janine Shepherd, Richard R. Gammon
Annals of Blood  
2026;
11:
14
.
Review Article 
Monoclonal B-cell lymphocytosis: what hematologists should know—a narrative review
Gabriel de Sousa Nobre, Lucas Cartaxo Tavares, Laura Azevedo de Moraes, Marina Almeida Simões, Daniel Mazza Matos
Annals of Blood  
2026;
11:
13
.
Review Article 
The history of hemoglobin-based oxygen carriers: a narrative review
Erica A. Swenson, Maryam Asif, Deborah Tolich, Gaurav K. Gupta, Joyisa Deb, Sarah Walbolt, Bruce Spiess
Annals of Blood  
2026;
11:
11
.